Peter Schellongowski

Dr. Peter Schellongowski


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2017 in Critical Care
Verified
Journal Article
Open access
PDF file
OGon behalf of the Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group
on behalf of the Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group
FKFrank Kroschinsky
Frank Kroschinsky
FSFriedrich Stölzel
Friedrich Stölzel
SBSimone von Bonin
Simone von Bonin
GBGernot Beutel
Gernot Beutel
PSPeter Schellongowski
Peter Schellongowski
Pharmacological and cellular treatment of cancer is changing dramatically with benefits for patient outcome and comfort, but also with new toxicity profiles. The majority of adverse events can be classified as mild or moderate, but severe and life-threatening complications requiring ICU admission also occur. This review will focus on pathophysiology, symptoms, and management of these events based on the available literature. While standard antineoplastic therapy is associated with immunosuppression and infections, some of the recent approaches induce overwhelming inflammation and autoimmunity. Cytokine-release syndrome (CRS) describes a complex of symptoms including fever, hypotension, and skin reactions as well as lab abnormalities. CRS may occur after the infusion of monoclonal or bispecific antibodies (MABs, BABs) targeting immune effectors and tumor cells and is a major concern in recipients of chimeric antigen receptor (CAR) modified T lymphocytes as well. BAB and CAR T-cell treatment may also be compromised by central nervous system (CNS) toxicities such as encephalopathy, cerebellar alteration, disturbed consciousness, or seizures. While CRS is known to be induced by exceedingly high levels of inflammatory cytokines, the pathophysiology of CNS events is still unclear. Treatment with antibodies against inhibiting immune checkpoints can lead to immune-related adverse events (IRAEs); colitis, diarrhea, and endocrine disorders are often the cause for ICU admissions. Respiratory distress is the main reason for ICU treatment in cancer patients and is attributable to infectious agents in most cases. In addition, some of the new drugs are reported to cause non-infectious lung complications. While drug-induced interstitial pneumonitis was observed in a substantial number of patients treated with phosphoinositol-3-kinase inhibitors, IRAEs may also affect the lungs. Inhibitors of angiogenetic pathways have increased the antineoplastic portfolio. However, vessel formation is also essential for regeneration and tissue repair. Therefore, severe vascular side effects, including thromboembolic events, gastrointestinal bleeding or perforation, hypertension, and congestive heart failure, compromise antitumor efficacy. The limited knowledge of the pathophysiology and management of life-threatening complications relating to new cancer drugs presents a need to provide ICU staff, oncologists, and organ specialists with evidence-based algorithms.

15 May 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MSMatthieu Schmidt
Matthieu Schmidt
PSPeter Schellongowski
Peter Schellongowski
NPNicolò Patroniti
Nicolò Patroniti
Fabio Silvio TacconeFabio Silvio Taccone
Fabio Silvio Taccone
DMDinis dos Reis Miranda
Dinis dos Reis Miranda
ACAlain Combes
Alain Combes
Rationale: Because encouraging rates for hospital and long-term survival of immunocompromised patients in ICUs have been described, these patients are more likely to receive invasive therapies, like extracorporeal membrane oxygenation (ECMO). Objectives: To report outcomes of immunocompromised patients treated with ECMO for severe acute respiratory distress syndrome (ARDS) and to identify their pre-ECMO predictors of 6-month mortality and main ECMO-related complications. Methods: Retrospective multicenter study in 10 international ICUs with high volumes of ECMO cases. Immunocompromised patients, defined as having hematological malignancies, active solid tumor, solid-organ transplant, acquired immunodeficiency syndrome, or long-term or high-dose corticosteroid or immunosuppressant use, and severe ECMO-treated ARDS, from 2008 to 2015 were included. Measurements and Main Results: We collected demographics, clinical data, ECMO-related complications, and ICU- and 6 month–outcome data for 203 patients (median Acute Physiology and Chronic Health Evaluation II score, 28 [25th–75th percentile, 20–33]; age, 51 [38–59] yr; PaO2/FiO2, 60 [50–82] mm Hg before ECMO) who fulfilled our inclusion criteria. Six-month survival was only 30%, with a respective median ECMO duration and ICU stay of 8 (5–14) and 25 (16–50) days. Patients with hematological malignancies had significantly poorer outcomes than others (log-rank P = 0.02). ECMO-related major bleeding, cannula infection, and ventilator-associated pneumonia were frequent (36%, 10%, and 50%, respectively). Multivariate analyses retained fewer than 30 days between immunodeficiency diagnosis and ECMO cannulation as being associated with lower 6-month mortality (odds ratio, 0.32 [95% confidence interval, 0.16–0.66]; P = 0.002), and lower platelet count, higher Pco2, age, and driving pressure as independent pre-ECMO predictors of 6-month mortality. Conclusions: Recently diagnosed immunodeficiency is associated with a much better prognosis in ECMO-treated severe ARDS. However, low 6-month survival of our large cohort of immunocompromised patients supports restricting ECMO to patients with realistic oncological/therapeutic prognoses, acceptable functional status, and few pre-ECMO mortality-risk factors.

20 January 2014 in Critical Care
Verified
Journal Article
Open access
PDF file
PWPhilipp Wohlfarth
Philipp Wohlfarth
RURoman Ullrich
Roman Ullrich
TSThomas Staudinger
Thomas Staudinger
ABAndja Bojic
Andja Bojic
OROliver Robak
Oliver Robak
A(Arbeitsgruppe Für Hämato-Onkologische Intensivmedizin der Österreichischen Gesellschaft Für Internistische Und Allgemeine Intensivmedizin Und Notfallmedizin (Ögiain)
Arbeitsgruppe Für Hämato-Onkologische Intensivmedizin der Österreichischen Gesellschaft Für Internistische Und Allgemeine Intensivmedizin Und Notfallmedizin (Ögiain)
Introduction: Acute respiratory failure (ARF) is the main reason for intensive care unit (ICU) admissions in patients with hematologic malignancies (HMs). We report the first series of adult patients with ARF and HMs treated with extracorporeal membrane oxygenation (ECMO). Methods: This is a retrospective cohort study of 14 patients with HMs (aggressive non-Hodgkin lymphoma (NHL) n = 5; highly aggressive NHL, that is acute lymphoblastic leukemia or Burkitt lymphoma, n = 5; Hodgkin lymphoma, n = 2; acute myeloid leukemia, n = 1; multiple myeloma, n = 1) receiving ECMO support because of ARF (all data as medians and interquartile ranges; age, 32 years (22 to 51 years); simplified acute physiology score II (SAPS II): 51 (42 to 65)). Etiology of ARF was pneumonia (n = 10), thoracic manifestation of NHL (n = 2), sepsis of nonpulmonary origin (n = 1), and transfusion-related acute lung injury (n = 1). Diagnosis of HM was established during ECMO in four patients, and five first received (immuno-) chemotherapy on ECMO. Results: Before ECMO, the PaO2/FiO2 ratio was 60 (53 to 65), (3.3 to 3.7). Three patients received venoarterial ECMO because of acute circulatory failure in addition to ARF; all other patients received venovenous ECMO. All patients needed vasopressors, and five needed hemofiltration. Thrombocytopenia occurred in all patients (lowest platelet count was 20 (11 to 21) G/L). Five major bleeding events were noted. ECMO duration was 8.5 (4 to 16) days. ICU and hospital survival was 50%. All survivors were alive at follow-up (36 (10 to 58) months); five patients were in complete remission, one in partial remission, and one had relapsed. Conclusions: ECMO therapy is feasible in selected patients with HMs and ARF and can be associated with long-term disease-free survival.

1 January 2016 in ESMO Open
Verified
Journal Article
Open access
PDF file
PSPeter Schellongowski
Peter Schellongowski
WSWolfgang R. Sperr
Wolfgang R. Sperr
PWPhilipp Wohlfarth
Philipp Wohlfarth
PKPaul N. Knoebl
Paul N. Knoebl
WRWerner Rabitsch
Werner Rabitsch
TSThomas Staudinger
Thomas Staudinger
This narrative review deals with the challenge of defining adequate therapy goals and intensive care unit (ICU) admission criteria for critically ill patients with cancer. Several specific complications of critically ill patients with cancer require close collaborations of intensive care and cancer specialists. Intensivists require a basic understanding of the pathophysiology, diagnosis and therapy of common cancer-specific problems. Cancer specialists must be knowledgeable in preventing, detecting and treating imminent or manifest organ failures. In case of one or more organ dysfunctions, ICU admissions must be evaluated early. In order to properly define the therapy goals for critically ill patients with cancer, decision-makers must be aware of the short-term intensive care prognosis as well as the long-term oncological options and perspectives. Multidisciplinary teamwork is key when it comes down to decisions on ICU admission, planning of therapeutic aims, patient management in the ICU and tailored therapy limiting with smooth transition into a palliative care (PC) setting, whenever appropriate.

8 November 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
GMGennaro Martucci
Gennaro Martucci
MGMarco Giani
Marco Giani
MSMatthieu Schmidt
Matthieu Schmidt
KTKenichi Tanaka
Kenichi Tanaka
ATAli Tabatabai
Ali Tabatabai
I(International ECMO Network (ECMONet)
International ECMO Network (ECMONet)
Definitive guidelines for anticoagulation management during veno-venous extracorporeal membrane oxygenation (VV ECMO) are lacking, while bleeding complications continue to pose major challenges. To describe anticoagulation modalities and bleeding events in adults receiving VV ECMO. International prospective observational study in 41 centers, from December 2018 to February 2021. Anticoagulation was recorded daily in terms of type, dosage, and monitoring strategy. Bleeding events were reported according to site, severity, and impact on mortality. The study cohort included 652 patients, and 8471 days on ECMO were analyzed. Unfractionated heparin (UFH) was the initial anticoagulant in 77% of patients, and the most used anticoagulant during the ECMO course (6221 days, 73%). Activated partial thromboplastin time (aPTT) was the most common test for monitoring coagulation (86% of days): the median value was 52 seconds (39-61), but dropped by 5.3 seconds after the first bleeding event (95% CI -7.4 to -3.2, p< 0.01). Bleeding occurred on 1202 days (16.5 %). Overall, 342 patients (52.5 %) experienced at least one bleeding event (one episode every 215 hours on ECMO), of which 10 (1.6%) were fatal. In a multiple penalized Cox proportional hazard model, higher aPTT was a potentially modifiable risk factor for the first episode of bleeding (for 20 seconds increase, hazard ratio 1.07). Anticoagulation during VV ECMO was a dynamic process, with frequent stopping in cases of bleeding, and restart according to the clinical picture. Future studies might explore lower aPTT targets to reduce the risk of bleeding.

6 July 2014 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
A(Arbeitsgruppe Für Hämato-Onkologische Intensivmedizin der Österreichischen Gesellschaft Für Internistische Und Allgemeine Intensivmedizin Und Notfallmedizin (Ögiain)
Arbeitsgruppe Für Hämato-Onkologische Intensivmedizin der Österreichischen Gesellschaft Für Internistische Und Allgemeine Intensivmedizin Und Notfallmedizin (Ögiain)
PWPhilipp Wohlfarth
Philipp Wohlfarth
TSThomas Staudinger
Thomas Staudinger
WSWolfgang R. Sperr
Wolfgang R. Sperr
ABAndja Bojic
Andja Bojic
PSPeter Schellongowski
Peter Schellongowski